Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897350816> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2897350816 abstract "Background: Familial hypercholesterolemia (FH) is an inherited autosomal dominant disorder that is characterized by substantially increased Low-Density Lipoprotein Cholesterol (LDL-C) levels. Patients with FH have a significantly higher risk for Cardiovascular (CV) events, and the timely reduction of LDL-C is of paramount importance to ameliorate the risk for CV disease. Among the available lipid-lowering therapies, the novel Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors have emerged as a very promising class of drugs for the management of such patients. Objective: The purpose of this review is to present available data on the efficacy and safety of the two available PCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs. Methods: A comprehensive literature search was performed to identify available data from clinical studies evaluating the impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH. Results: Several studies have assessed the lipid-lowering profile of PCSK9 inhibitors in patients with FH. Both evolocumab and alirocumab were found to significantly reduce LDL-C by more than 50-60% in FH patients. Furthermore, data also support a lower rate of lipid apheresis in FH patients receiving a PCSK9 inhibitor. In terms of CV outcomes, both drugs were found to possess CV-ameliorating effects of the same extent in patients with CV disease. However, alirocumab reduced all-cause mortality, as well, a finding not observed with evolocumab. Several differences in the study population characteristics might explain this and other mild differences observed in the CV trials of these drugs. Conclusion: Available evidence suggests similar potency of alirocumab and evolocumab in reducing lipids and CV events." @default.
- W2897350816 created "2018-10-26" @default.
- W2897350816 creator A5005918993 @default.
- W2897350816 creator A5033451188 @default.
- W2897350816 creator A5037285876 @default.
- W2897350816 creator A5055351747 @default.
- W2897350816 creator A5070120036 @default.
- W2897350816 creator A5091336195 @default.
- W2897350816 date "2019-01-02" @default.
- W2897350816 modified "2023-10-14" @default.
- W2897350816 title "Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia" @default.
- W2897350816 doi "https://doi.org/10.2174/1381612824666181010124657" @default.
- W2897350816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30317985" @default.
- W2897350816 hasPublicationYear "2019" @default.
- W2897350816 type Work @default.
- W2897350816 sameAs 2897350816 @default.
- W2897350816 citedByCount "8" @default.
- W2897350816 countsByYear W28973508162019 @default.
- W2897350816 countsByYear W28973508162020 @default.
- W2897350816 countsByYear W28973508162021 @default.
- W2897350816 countsByYear W28973508162022 @default.
- W2897350816 crossrefType "journal-article" @default.
- W2897350816 hasAuthorship W2897350816A5005918993 @default.
- W2897350816 hasAuthorship W2897350816A5033451188 @default.
- W2897350816 hasAuthorship W2897350816A5037285876 @default.
- W2897350816 hasAuthorship W2897350816A5055351747 @default.
- W2897350816 hasAuthorship W2897350816A5070120036 @default.
- W2897350816 hasAuthorship W2897350816A5091336195 @default.
- W2897350816 hasConcept C126322002 @default.
- W2897350816 hasConcept C2778096610 @default.
- W2897350816 hasConcept C2778114629 @default.
- W2897350816 hasConcept C2778163477 @default.
- W2897350816 hasConcept C2778849439 @default.
- W2897350816 hasConcept C2779120738 @default.
- W2897350816 hasConcept C2779134260 @default.
- W2897350816 hasConcept C2780072125 @default.
- W2897350816 hasConcept C2780745583 @default.
- W2897350816 hasConcept C2780902209 @default.
- W2897350816 hasConcept C2780948078 @default.
- W2897350816 hasConcept C2908647359 @default.
- W2897350816 hasConcept C43554185 @default.
- W2897350816 hasConcept C71924100 @default.
- W2897350816 hasConcept C98274493 @default.
- W2897350816 hasConcept C99454951 @default.
- W2897350816 hasConceptScore W2897350816C126322002 @default.
- W2897350816 hasConceptScore W2897350816C2778096610 @default.
- W2897350816 hasConceptScore W2897350816C2778114629 @default.
- W2897350816 hasConceptScore W2897350816C2778163477 @default.
- W2897350816 hasConceptScore W2897350816C2778849439 @default.
- W2897350816 hasConceptScore W2897350816C2779120738 @default.
- W2897350816 hasConceptScore W2897350816C2779134260 @default.
- W2897350816 hasConceptScore W2897350816C2780072125 @default.
- W2897350816 hasConceptScore W2897350816C2780745583 @default.
- W2897350816 hasConceptScore W2897350816C2780902209 @default.
- W2897350816 hasConceptScore W2897350816C2780948078 @default.
- W2897350816 hasConceptScore W2897350816C2908647359 @default.
- W2897350816 hasConceptScore W2897350816C43554185 @default.
- W2897350816 hasConceptScore W2897350816C71924100 @default.
- W2897350816 hasConceptScore W2897350816C98274493 @default.
- W2897350816 hasConceptScore W2897350816C99454951 @default.
- W2897350816 hasLocation W28973508161 @default.
- W2897350816 hasLocation W28973508162 @default.
- W2897350816 hasOpenAccess W2897350816 @default.
- W2897350816 hasPrimaryLocation W28973508161 @default.
- W2897350816 hasRelatedWork W2014763322 @default.
- W2897350816 hasRelatedWork W2162657286 @default.
- W2897350816 hasRelatedWork W2563170303 @default.
- W2897350816 hasRelatedWork W2573186328 @default.
- W2897350816 hasRelatedWork W2585426472 @default.
- W2897350816 hasRelatedWork W2589793923 @default.
- W2897350816 hasRelatedWork W2616658146 @default.
- W2897350816 hasRelatedWork W2620969414 @default.
- W2897350816 hasRelatedWork W2752864344 @default.
- W2897350816 hasRelatedWork W3122358138 @default.
- W2897350816 isParatext "false" @default.
- W2897350816 isRetracted "false" @default.
- W2897350816 magId "2897350816" @default.
- W2897350816 workType "article" @default.